Figure 3From: Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Kaplan-Meier estimates of overall survival (A) and progression-free survival (B) for 43 relapsed/primary refractory DLBCL patients treated with rituximab-salvage therapy identified by the saaIPI as intermediate risk (saaIPI =1-2) were further stratified into low or high groups by the ALC/AMC ratio. Back to article page